Midday Report: PolarityTE (PTE) Falls on August 4
Equities Staff Follow |PolarityTE Inc (NASDAQ: PTE) shares are down 8.98%, or $0.15 per share, as on 12:00:37 est today. Since opening the day at $1.68, 174,519 shares of PolarityTE have exchanged hands and the stock has traded between $1.68 and $1.47.
Already this year the company is down 88.62%.
PolarityTE anticipates its next earnings on 2022-08-11.
For technical charts, analysis, and more on PolarityTE visit the company profile.
About PolarityTE Inc
PolarityTE is focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures products from the patient's own tissue and uses the patient's own body to support the regenerative process. From a small piece of healthy autologous tissue, the company creates a dynamic and self-propagating product designed to regenerate the target tissues. PolarityTE's innovative method is intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing.
To get more information on PolarityTE Inc and to follow the company's latest updates, you can visit the company's profile page here: PolarityTE Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.
Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.
Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer